Business Intelligence Analyst II - Nashville, TN
McKesson Corporation | |
United States, Tennessee, Nashville | |
Jan 02, 2025 | |
It's More Than a Career, It's a Mission. Our people are the foundation of our success. By joining our growing team at Sarah Cannon Research Institute (SCRI), a subsidiary of McKesson, you will have the opportunity to become part of one of the largest community-based cancer programs to advance oncology treatments and improve outcomes for cancer patients across the globe. We look for mission-driven candidates who have a desire to advance the fight against cancer and make a difference in the lives of patients diagnosed with cancer every day. Our Mission People who live with cancer - those who work to prevent it, fight it, and survive it - are at the heart of every decision we make. Bringing the most innovative medical minds together with the most passionate caregivers in their communities, we are transforming care and personalizing treatment. Through clinical excellence and cutting-edge research, SCRI is redefining cancer care around the world. Our Business Analyst II will serve as a primary contact with our lines of business and functions within the organization for providing overall business, technical, and strategic architecture information and impact analysis. This includes recognized business knowledge in analyzing and collaborating on new business opportunities and information technology solutions that enable the organization to achieve its goals. Works with other key project team members to define requirements, design the functional solution, identify and resolve project issues, and ensure the solutions meet the business needs and requirements. This position will be based 3 days per week at our Corporate HQ in Nashville, TN and 2 days per week remote. Duties include but are not limited to:
Minimum Qualifications:
About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 750 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI's research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S. Please click here to learn more about our research offerings. We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status. |